These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 11299029)
1. Universal leukodepletion of blood and febrile transfusion reactions. Rennie I; Rawlinson PS; Clark P Transfus Med; 2001 Apr; 11(2):115. PubMed ID: 11299029 [No Abstract] [Full Text] [Related]
2. Perspective on Nordic views on selective/universal leukodepletion. Flesland O Transfus Sci; 1998 Dec; 19(4):355-7. PubMed ID: 10351154 [No Abstract] [Full Text] [Related]
3. International views on universal leucodepletion: the perspective in Portugal. de Sousa G Transfus Sci; 1998 Dec; 19(4):351-2. PubMed ID: 10351152 [No Abstract] [Full Text] [Related]
4. International views on universal leucodepletion: the perspective in Germany. Seitz MD Transfus Sci; 1998 Dec; 19(4):359-60. PubMed ID: 10351155 [No Abstract] [Full Text] [Related]
6. Operational and research approaches to universal leucodepletion in Scotland. Prowse C Transfus Sci; 1998 Dec; 19(4):367-9. PubMed ID: 10351158 [No Abstract] [Full Text] [Related]
7. Prions and blood transfusion. Barbara J Transfus Sci; 2000; 22(1-2):49. PubMed ID: 10771380 [No Abstract] [Full Text] [Related]
8. Logistical problems of supplying leucodepleted blood components within the national blood service. Tandy N Transfus Sci; 1998 Dec; 19(4):373-4. PubMed ID: 10351160 [No Abstract] [Full Text] [Related]
9. NBS approaches to the approval of suppliers of leucodepletion systems. Smith KJ Transfus Sci; 1998 Dec; 19(4):371-2. PubMed ID: 10351159 [No Abstract] [Full Text] [Related]
11. International views on universal leucodepletion: the perspective in NBS, England. Wallington T Transfus Sci; 1998 Dec; 19(4):347-8. PubMed ID: 10351150 [No Abstract] [Full Text] [Related]
12. Validation approaches selective/universal leucodepletion: the need for standardised validation strategies. Seghatchian MJ; Krailadsiri P Transfus Sci; 1998 Dec; 19(4):363-5. PubMed ID: 10351157 [No Abstract] [Full Text] [Related]
13. The risk of transmission of nvCJD by blood transfusion and the potential benefits of leucodepletion. Turner M Transfus Sci; 1998 Dec; 19(4):331-2. PubMed ID: 10351147 [No Abstract] [Full Text] [Related]
14. Management of blood donors with a low level of exposure to vCJD. Pasqualetti D; Ghirardini A; Bellocco R; Vaglio S; Gozzer M; Girelli G Haematologica; 2001 Mar; 86(3):E04. PubMed ID: 11255291 [No Abstract] [Full Text] [Related]
15. International views on universal leucodepletion: the perspective in NBS, Ireland. Murphy W Transfus Sci; 1998 Dec; 19(4):349-50. PubMed ID: 10351151 [No Abstract] [Full Text] [Related]
16. Universal leukodepletion of blood components results in a significant reduction of febrile non-hemolytic but not allergic transfusion reactions. Pruss A; Kalus U; Radtke H; Koscielny J; Baumann-Baretti B; Balzer D; Dörner T; Salama A; Kiesewetter H Transfus Apher Sci; 2004 Feb; 30(1):41-6. PubMed ID: 14746820 [TBL] [Abstract][Full Text] [Related]
17. Selective or universal leucodepletion: the Italian experience. Accorsi P; Iacone A Transfus Sci; 2000; 22(1-2):65-7. PubMed ID: 10771386 [No Abstract] [Full Text] [Related]